New drug cocktails aim to fight advanced lung cancer
NCT ID NCT05676931
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing several immunotherapy drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations can shrink tumors and improve survival. About 400 participants will receive different drug mixes, including domvanalimab, zimberelimab, and chemotherapy. The study is currently active but no longer recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
domvanalimab, quemliclustat, zimberelimab, docetaxel, platinum-based doublet
What this could lead to
If successful, this could lead to more effective treatment options for advanced lung cancer, potentially improving survival and quality of life.
What could go wrong
This is an early-phase trial with only 400 participants, so results may not apply to all patients. Immunotherapy combinations can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 138-736, South Korea
-
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)
Pesaro, Italy
-
Barts Health NHS Trust St Bartholomew's Hospital
London, W1G 6AF, United Kingdom
-
CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque
Bordeaux, 33604, France
-
Cancer Research SA Pty Ltd
Adelaide, South Australia, 5000, Australia
-
Caucasus Medical Center
Tbilisi, Georgia
-
Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie
Warsaw, Poland
-
Chonam National University Hwasun Hospital
Hwasun-gun, 58128, South Korea
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Complejo Hospitalario Universitario Insular Materno Infantil De Gran Canaria
Las Palmas de Gran Canaria, 35016, Spain
-
E-DA Healthcare Group E-DA Hospital
Kaoshiung, 970, Taiwan
-
Florida Cancer Specialists (Administration and Drug Shipment)
The Villages, Florida, 32163, United States
-
Fondazione IRCCS Istituto Nazionale dei tumori di Milano
Rome, Italy
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hopital FOCH
Suresnes, France
-
Hospices Civils de Lyon Centre Hospitalier Lyon Sud
Lyon, 69495, France
-
Hospital 9 de Octubre Vithas Valencia
Valencia, 46015, Spain
-
Hospital Quirónsalud Málaga
Málaga, Spain
-
Hospital Universitari Mutua Terrassa
Barcelona, 8221, Spain
-
Hospital Universitario De La Virgen De Valme
Seville, 41001, Spain
-
Hospital Universitario Lucus Augusti
Lugo, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hospital Universitario y Politécnico la Fe
Valencia, 46026, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 8041, Spain
-
Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation
Hualien City, 970, Taiwan
-
Institut De Cancerologie Strasbourg Europe ICANS
Strasboug, 67033, France
-
Israel Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
-
Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST
Meldola, Italy
-
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
-
Korea University Guro Hospital
Seoul, 08308, South Korea
-
LTD High Technology Hospital Medcenter
Batumi, Georgia
-
Ltd Pineo Medical Ecosystem
Tbilisi, Georgia
-
Mackey Memorial Hospital
Taipei, 104, Taiwan
-
Medical Oncology Associated, PS (dba Summit Cancer Centers)
Spokane, Washington, 99208, United States
-
Medpolonia Sp. Z.o.o.
Poznan, Poland
-
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021, United States
-
National Taiwan University Hospital Yumlin Branch
Yunlin County, Taiwan
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Ochsner Clinic Foundation
Jefferson, Louisiana, 70121, United States
-
Pindara Private Hospital
Benowa, Queensland, 4217, Australia
-
Samsung Changwon Hospital
Changwon-Si, South Korea
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
Szpitale Pomorskie sp. z o.o
Gdynia, Poland
-
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
New Taipei City, 23561, Taiwan
-
The Border Cancer Hospital
Albury, New South Wales, Australia
-
UOMI Cancer Centre
Barcelona, Spain
-
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, 35294, United States
-
University of California San Diego (UCSD)
La Jolla, California, 92093, United States
-
Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego
Katowice, Poland
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States
-
stituto Nazionale per lo Studio e la Cura dei Tumori
Milan, Italy